Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

2016 ASCO Annual Meeting /
CPX-351 improves outcomes for refractory AML

3rd - 7th Jun 2016

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 06.06.16
Views: 1769
Rating:

Dr Jeffrey Lancet - H. Lee Moffitt Cancer Center, Tampa, USA

Dr Lancet speaks with ecancertv at ASCO 2016 to discuss a new formulation of cytarabine and daunorubicin titled CPX-351.

Compared to the current 7 3 schedule of cytrarabine and daunorubicin, Dr Lancet reports improved patient response, reduced mortality and no difference in toxicity.

For elderly patients with refractory AML, Dr Lancet reports that CPX-351 should become the new standard of care.

ecancer's filming at ASCO 2016 has been kindly supported by Amgen through the ECMS Foundation. ecancer is editorially independent and there is no influence over content.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation